Mronj Güncel Tedavi Yaklaşımları

Fleisher KE, Welch G, Kottal S, et al: Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110:509, 2010

Wehrhan F, Gross C, Creutzburg K, et al: Osteoclastic expression of higher-level regulators NFATc1 and BCL6 in medication- related osteonecrosis of the jaw secondary to bisphosphonate therapy: A comparison with osteoradionecrosis and osteomyelitis. J Transl Med 17:69, 2019.

de Molon RS, Shimamoto H, Bezouglaia O, et al: OPG-Fc but not zoledronic acid discontinuation reverses osteonecrosis of the jaws (ONJ) in mice. J Bone Miner Res 30:1627, 2015

Hadaya D, Soundia A, Gkouveris I, et al: Antiresorptive-type and discontinuation-timing Affect ONJ burden. J Dent Res 100:746, 2021

Ishtiaq S, Edwards S, Sankaralingam A, et al: The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells. Cytokine 71:154, 2015

Kun-Darbois JD, Libouban H, Mabilleau G, et al: Bone mineralization and vascularization in bisphosphonate-related

Gao SY, Lin RB, Huang SH, et al: PDGF-BB exhibited therapeutic effects on rat model of bisphosphonate-related osteonecrosis of the jaw by enhancing angiogenesis and osteogenesis. Bone 144:115117, 2021

8.Bi Y, Gao Y, Ehirchiou D, et al: Bisphosphonates cause osteonecrosis of the jaw-like disease in mice. Am J Pathol 177:280, 2010.

Gkouveris I, Hadaya D, Soundia A, et al: Vasculature submucosal changes at early stages of osteonecrosis of the jaw (ONJ). Bone 123:234, 2019

Ruggiero SL, Dodson TB, Fantasia J, et al: American Association of Oral and Maxillofacial Surgeons position paper on medication- related osteonecrosis of the jaw–2014 update. J Oral Maxillofac Surg 72:1938, 2014

Hadaya D, Soundia A, Freymiller E, et al: Nonsurgical management of medication-related osteonecrosis of the jaws using local wound care. J Oral Maxillofac Surg 76: 2332, 2018

Coropciuc RG, Grisar K, Aerden T, et al: Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases:

Conservative treatment is effective up to stage 2. Br J Oral Maxillofac Surg 55:787, 2017

Soundia A, Hadaya D, Mallya SM, Aghaloo TL, Tetradis S: Radiographic predictors of bone exposure in patients with stage 0 medication-related osteonecrosis of the jaws. Surg Oral Med Oral Pathol Oral Radiol 126(6), 2018

Varoni EM, Lombardi N, Villa G, et al: Conservative management of medication-related osteonecrosis of the jaws (MRONJ): A retrospective cohort study. Antibiotics (Basel) 10, 2021

Carlson ER: Management of antiresorptive osteonecrosis of the jaws with primary surgical resection. J Oral Maxillofac Surg 72:655, 2014

Watters AL, Hansen HJ, Williams T, et al: Intravenous bisphosphonate- related osteonecrosis of the jaw: Long-term follow-up of 109 patients. Oral Surg Oral Med Oral Pathol Oral Radiol 115:192, 2013

Kyrgidis A, Vahtsevanos K, Koloutsos G, et al: Bisphosphonaterelated osteonecrosis of the jaws: A case-control study of risk factors in breast cancer patients. J Clin Oncol 26:4634, 2008

Di Fede O, Canepa F, Panzarella V, Mauceri R, Del Gaizo C, Bedogni A, Fusco V, Tozzo P, Pizzo G, Campisi G, Galvano A. The Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review with a Pooled Analysis of Only Surgery versus Combined Protocols. Int J Environ Res Public Health. 2021 Aug 10;18(16):8432.

Słowik Ł, Totoń E, Nowak A, Wysocka-Słowik A, Okła M, Ślebioda Z. Pharmacological Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) with Pentoxifylline and Tocopherol. J Clin Med. 2025 Feb 3;14(3):974.

Kim RY, Hong SO, Jung JW, Lee MH, Lee YK, Jee YJ. Successful treatment of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw: a report of two cases. J Korean Assoc Oral Maxillofac Surg. 2024 Oct 31;50(5):285-291.

Park JH, Park W, Nguyen LP, Kim JW, Cho S, Jo H, Kim HJ, Jung YS, Kim JY. Treatment period and changes in bone markers according to the application of teriparatide in treating medication-related osteonecrosis of the jaw. BMC Oral Health. 2025 Apr 11;25(1):528.

Boffano P, Agnone AM, Neirotti F, Bonfiglio R, Brucoli M, Ruslin M, Durković A, Milosavljević M, Konstantinovic V, Rodríguez JCV, Santamarta TR, Meyer C, Louvrier A, Michel-Guillaneux A, Bertin E, Starch-Jensen T, Tadic AJ, Bajkin BV, Dugast S, Bertin H, Corre P, Szalma J, Dovsak T, Prodnik L, Mottl R, Dediol E, Kos B, Ontanon AV, Stathopoulos P, Tsekoura K, Polcyn A, Michcik A, Zaleckas L, Pavlov N, Sapundzhiev A, Uchikov P, Pechalova P. Epidemiology, etiopathogenesis, and management of MRONJ: A European multicenter study. J Stomatol Oral Maxillofac Surg. 2024 Sep;125(12 Suppl 2):101931.

Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons' Position Paper on Medication-Related Osteonecrosis of the Jaws-2022 Update. J Oral Maxillofac Surg. 2022 May;80(5):920-943.